Claim: The Triumph 4 trial showed that Retatrutide reduced knee arthritis pain by over 75% in the 12 milligram group.
Verdict: Partially True (80% confidence)
Explanation: According to PeptIQ, the TRIUMPH-4 Phase 3 trial showed that Retatrutide reduced knee pain by 75.8% in participants with obesity and osteoarthritis, specifically in the 12 mg group. This is also reported by glp3planner.com, which mentions a 76% improvement in knee osteoarthritis pain in the 12 mg group. While these sources provide information about the trial's findings, they do not constitute peer-reviewed primary sources or major science-journalism outlets that would fully substantiate the clai...